Research Laboratory

Available funding for residents (if any):

• none

Extramural funding obtained by lab residents within last 3 years:

• none

Available projects (one sentence per project):

• Dendritic cell vaccines for breast cancer and melanoma
• Mechanisms of dendritic cell activation
• Interactions between dendritic cells, regulatory T cells, and tumor stroma

Current lab residents (expected completion date):

• Anupama Sharma, MD (2010)

Past lab residents, within 3 years (completion date):

• Robert E. Roses, MD
• Mark Faries, MD
• Isabelle Bedrosian, MD
  American Association of Cancer Research Young Investigator Award
• Friederica Engels, MD

National meetings where your residents have given oral presentations within last 3 years:

• Society of Surgical Oncology
• American Association for Cancer Research
• Society of Nuclear Medicine
• American College of Surgeons
• American Society of Hematology
• American Society of Clinical Oncology

Resident publications (not abstracts) within last 3 years:

Lee SG. Orel SG. Woo IJ. Cruz-Jove E. Putt ME. Solin LJ. Czerniecki BJ. Schnall MD. MR imaging screening of contralateral breast in patients with newly diagnosed breast cancer: Preliminary results. Radiology 226(3):773-778, Mar. 2003.

Bedrosian I, Schlencker J, Mick R, Orel S, Schnall M, Reynolds C, Spitz FR, Callans L, Buzby GP, Rosato EF, Fraker DL, Czerniecki BJ. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98(3):468-473, Aug. 1, 2003.

Xu S, Koski GK, Faries MB, Bedrosian I, Mick R, Maeurer M, Chever, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8 + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL- 12 dependent mechanism. Journal of Immunology 171(5):2251-2261, Sept. 1, 2003.

Bedrosian IB, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T cell function in melanoma patients. Journal of Clinical Oncology 21(20):3826-3835, Oct. 15, 2003.

Koski GK, Kariko K, Xu S, Weissman D, Cohen PA, Czerniecki BJ, Cutting Edge: Innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. The Journal of Immunology, 2004, 172: 3989-3993, 2004.

Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xiaowei Xu, Czerniecki B, Spitz F, Schucter L, Elder, D. Thin primary cutaneous malignant melanoma: A prognostic tree for ten metastasis is more accurate than AJCC staging. Journal of Clinical Oncology 2004, 22: 3668-3676.

Kesmodel SB, Karakousis GC, Botbyl, JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi, A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz, FR. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanoma. Annals of Surgical Oncology 12: 449-458 2005.

Bedrosian, I. Czerniecki BJ. Change in surgical Management of breast cancer patients based on preoperative MR imaging Am J Onc Rev, 2004; 3(4):209.

Downes K, Glatt BS, Kanchwala SK, Mick R, Fraker DL, Fox KR, Solin LJ, Bucky LP, Czerniecki BJ. Skin-sparing mastectomy and immediate reconstruction as an acceptable treatment option for high-risk breast cancer patients. Cancer 2005.

Koski, GK, and Czerniecki BJ. Combining innate immunity with radiation therapy for cancer treatment. Clinical Can Res. 2005, 11: 7-11.

Chance B, Nioka S, Zhang J, Conant EF, Hwang E, Briest SG, Orel SG, Schnall MD, Czerniecki BJ. Breast Cancer Detection based on incremental biochemical and physiological properties of breast cancers a six-year, two-site study. Acad Radiol 2005; 12(8):925-933.

Choe R, Corlu A, Lee K, Durduran T, Konecky SD, Grosicka-Koptyra M, Arridge S, Czerniecki BJ, Fraker DL, DeMichele A, Chance B, Rosen M, Yodh A. Diffuse optical Tomography of breast cancer during neoadjuvant chemotherapy: a case study in comparison to MRI. Medical Physics 32:1128-1139 2005.

Jackson BM, Kim S, Davidson R, Schuchter L, Acs G, Czerniecki BJ. Re-operative sentinel lymph node biopsy: a case report. Clinical Breast Cancer 6: 530-532 2006.

Durduran, T, Choe R, Yu, G, Zhou C, Tchou, J, Czerniecki BJ, Yodh, A. Diffuse optical measurement of blood flow in breast tumors. Optics Letters 2005, 30:2915-2917.

Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, VanBelle P, Hotz, Elder DE, Marincola FM, Schuchter, L, Guerry D, Czerniecki BJ, Herlyn D. HLA-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res. 2006; 66:3287-3293.

Karakousis GC, Gimotty PA, Botbyl, Kesmodel SB, Elder DE, Ming ME, Guerry D, Fraker DL, Czerniecki BJ, Spitz FR. Predictors of regional nodal disease in patients with thin melanomas. Annals of Surgical Oncology 13: 533-541 2006.

Kesmodel SB, Canter RJ, Terhune KP, Bauer TW, Mick R, Rosato EF, Spitz FR, Fraker DL, Alavi A, Czerniecki BJ. Use of radiotracer for sentinel lymph node mapping in breast cancer optimizes staging independent of site of administration. Clinical Nuclear Medicine 31:1-7 2006.

Xu S, Koldovsky U, Xu M, Wang D, Fitzpatrick E, Son G, Koski G, Czerniecki BJ. Toll receptor 8 signaling primes myeloid dendritic cells for high level IL-12 production. Surgery 140:170-178 2006.

Gimotty, PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D. Biologically-based prognostic factors improve risk discrimination in patients with thin (=1.00) invasive cutaneous melanoms. (Submitted for Publication).

Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, Czerniecki B, Schnall M, Alavi A. Dual time point FDG-PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes of the lesions. J. Nuclear Medicine 47: 1440-1446 2006.

Zhang T, Somasundarum R, Caputo, L, VanBelle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Klara B, Rani P, Marincola F, Qiu R, Herlyn D. Preferential Involvement of CX Chemokine Receptor 4 and CX Chemokine Ligand 12 in T-cell migration toward melanoma cells. Cancer Biology & Therapy (In Press).

Czerniecki BJ, Xu M, Koski G. Neoadjuvant Therapy for HER-2/neu-expressing ductal carcinoma in situ using type 1 polarized dendritic cell vaccines. Breast Diseases: A Yearbook Quarterly 17: 320-323 2007.

Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged IL-12 burst secretion. Cancer Res (In Press).

Roses R, Xu M, Xu S, Koldovsky U, Son G, Koski GK, Czerniecki BJ. Working towards the development of cancer vaccines for the treatment and prevention of breast cancer. Current Cancer Therapy Reviews (In Press).